Covis Pharma is a global specialty pharmaceutical company

 

Our patients are our paramount concern. We market therapeutic solutions for patients with life-threatening conditions and chronic illnesses

Team

Covis is led by one of the strongest and longest-tenured senior management teams committed to delivering therapeutic solutions to improve the lives of its patients.

Strategic partners

Through its operational excellence, Covis is the preferred partner to world-class pharmaceutical companies and contract manufacturing organizations.

Product portfolio

Covis offers a portfolio of pharmaceutical products providing patients with affordable and therapeutically equivalent medications of select brands.

About Covis

At Covis, our paramount concern is patients’ outcomes as we focus on improving the health of people with serious medical conditions.

Covis is always evaluating products and corporate acquisition opportunities. Covis is well-capitalized and has significant resources committed from its equity sponsors for tack-on deals and larger transaction opportunities.

 

Click here to access our California Compliance Statement and Declaration.

Company and product history

Founded by Cerberus Capital Management in 2011, the investment management firm with over $30 billion in assets under management.
2018:
Covis Pharma acquired Global rights for Alvesco® , Omaris® , and Zetonna®.
2020:
Acquired by Apollo Global Management, Covis Pharma Group completed the acquisition of AMAG pharmaceuticals.
2021:
Further expanding product offerings through acquisition of addition products in various therapeutic areas.

Team

Michael Porter is the CEO of Covis Pharma. Previously he was COO of Covis Pharma Sarl, where he was responsible for the partial monetization of the business for $1.2 billion. He has over 20 years of private equity experience. Prior to Covis, Michael was with Cerberus Capital Management where he was a Senior Operating Executive.

He was previously with another large distressed private equity fund and began his career at AlixPartners in their Turnaround and Performance Improvement Group.

Michael received his MBA from Columbia Business School with a concentration in Finance via the accelerated program. In addition, he studied International Business at Senshu University in Kawasaki, Japan. Michael speaks English, Spanish, Portuguese, French, Japanese, and Russian.

Martin Cepeda is the Chief Human Resources Officer of Covis Pharma. Prior to joining Covis, Martin worked at AstraZeneca as Head of Human Resources for the Europe Oncology Business, based in Zug, Switzerland, >$2 billion in annual revenue and ~1,750 employees. He was also a member of AstraZeneca’s Inclusion and Diversity (I&D) Council chaired by the CEO, driving the company’s global I&D strategy. Martin brings over 16 years of Global HR experience across multinational pharmaceutical and life science companies.

Prior to AstraZeneca, Martin worked in HR roles of increasing responsibility at Johnson & Johnson and Wyeth (acquired by Pfizer in 2009). In those companies, he held roles in HR Data, Insights and Analytics, Talent Acquisition, and various HR Business Partner roles based in the U.S. and Europe.

Martin received his B.S. in Business Management from Penn State University and his MBA in International Business from Villanova University, both located in the U.S.

Raghav Chari has 25 years’ experience in the biopharmaceutical arena. Over this period, he has successfully built and led small and large organizations across the R&D and commercialization continuum.

Over the last 5 years, he has founded and continues to be involved in several startups that work at the interface between drug discovery and technology. All these startups seek to improve how novel products are discovered and developed by utilizing approaches involving machine learning, quantum mechanics and various technologies for personalized medicine.

From 2009 through 2016, he was President of Promius Pharma, a dermatology and neurology company, and Executive Vice President of Proprietary Products at Dr. Reddy’s Laboratories. In this role he built an integrated R&D and Commercial business which led to several first cycle NDA approvals for products that were developed organically from inception through commercial launch.

He has also been responsible for over 50 licensing and product development deals in the biopharmaceutical space. Early in his career, Raghav worked at McKinsey and Company, followed by stints at two small drug discovery/early development-stage biotech companies where he played hybrid R&D and commercial roles.

Raghav has a PhD in Physics from Princeton University, and a BS in Mathematics from the California Institute of Technology.

Fabio Fazio is Executive Vice President, Quality Assurance and Technology Transfers. He ensures compliance of pharmaceutical production to good manufacturing practice and to Marketing Authorizations. Fabio is responsible for the implementation of the quality systems which include the management of regulatory inspections, supplier oversight and audits, technology transfers, and adherence to good distribution practice.

Prior to Covis, Fabio worked at Biogen Idec as Qualified Person and in other technical CMC roles. Previous experiences encompass Process Development at GlaxoSmithKline in support of early stage clinical trials and basic research of novel therapeutic agents at the Scripps Research Institute in La Jolla, CA.

Fabio graduated from the Faculty of Pharmacy at the University of Siena, Italy, and received his Ph.D. in Chemistry from the University of Wuppertal, Germany.

Jim is currently the Senior Vice President and General Manager at Covis Pharma Canada, EU and ROW. Prior to joining Covis, Jim held senior level commercial roles at several multinational pharmaceutical companies, and has more than 30 years of pharmaceutical industry experience in general management, sales, marketing, market access, operations and business development.

In 2017, Jim was inducted into the Canadian Pharmaceutical Marketers Hall of Fame for his contributions to the industry and his support in the development of others.

For the past 8 years, Jim has been a seasonal lecturer in the MBA program at the DeGroote School of Business in Hamilton, Ontario.

Jim received his Bachelor of Engineering Science degree from the University of Western Ontario and Master of Business Administration from McMaster University.

Aziza Johnson is the Executive Vice President of Regulatory and Scientific Affairs. She has over 18 years of progressive global regulatory experience in the pharmaceutical industry leading project teams from early development through to commercial launch. Aziza has been active in all her roles and has led projects through start up, launch, survival, and growth.

Prior to Covis, Aziza worked in a variety of environments (small, medium, and large pharmaceutical organizations) with increasing roles and responsibility and in more recent years, including management roles. In addition, Aziza worked at the Medicines and Healthcare Regulatory Agency as a pharmaceutical assessor, where she gained useful insight into the operations of the UK Regulatory agency. Aziza attended the University of London School of Pharmacy and the University of Leicester where she received her B.Pharm. (Hons.) and Masters in Law respectively.

Nick Kelly is the Senior Vice President of Supply Chain. He has over 20 years of supply chain experience as a management consultant across multiple industries as well as within the pharmaceutical industry across branded, generics and medical device organizations.

Prior to Covis, Nick held several senior management roles at the regional & global level within the pharmaceutical industry, including Cardinal Health, Teva and Johnson & Johnson.

He has solid strategic, tactical and operational management experience, developing and maintaining relationships across the E2E supply chain to ensure an efficient operation.

Nick attended the University of Westminster where he received his BSc (Hons) in Business Information Technology.

Ozgur Kilic is the Global CFO of Covis Pharma. Previously Ozgur was the CFO of Vertice Pharma, a specialty generic pharma company in the U.S., backed by Warburg Pincus. Ozgur brings over 17 years of healthcare finance experience ranging from branded and generic pharmaceuticals to vaccines and medical devices both in the U.S. and Europe.

Prior to Vertice, Ozgur spent 14 years at Novartis in progressive Finance roles including Country and Region CFO roles in Switzerland, U.K., Italy and the U.S. He has significant experience in partnering with commercial, manufacturing, R&D and BD&L / M&A teams at operational and strategical level to drive business results.

Ozgur received his B.A. in Business Administration from Koc University in Turkey, MBA in Finance and Investment with distinction from Stuttgart Institute of Management Technology (SIMT), Germany and Executive Education in Finance from Harvard Business School. Ozgur is a Chartered Management Accountant (CIMA UK) and speaks English, Turkish, Italian and German.

Francesco Tallarico is the General Counsel and Group Corporate Secretary of Covis Pharma Group.

Prior to joining Covis, Mr. Tallarico served as the Chief Legal Officer and Corporate Secretary at The Flowr Corporation, a federally licensed global cannabis producer listed on the TSX-V. At Flowr, Mr. Tallarico managed all aspects of the legal and regulatory function of the company, including having led the company’s M&A and corporate finance transactions valued at over CAD$340 million.

Prior to Flowr, Mr. Tallarico served as the Chief Legal Officer and Corporate Secretary at Concordia International Corp. (now Advanz Pharma), a global specialty pharmaceutical company previously listed on the TSX and NASDAQ. At Concordia, Mr. Tallarico led the global legal and compliance functions, including having led Concordia’s M&A transactions valued at over USD$4.5 billion and corporate restructuring that resulted in Concordia reducing its debt by approximately USD$2.4 billion. Before joining Concordia, Mr. Tallarico practiced law in Toronto at Fasken Martineau DuMoulin LLP, specializing in corporate finance, M&A and securities matters.

Mr. Tallarico received his Bachelor of Arts from the University of Toronto and his Juris Doctor from the University of Windsor.

Al Tenuto is the US President for Covis Pharma. He has more than 20 years of experience in the pharmaceutical industry and more than 15 years focused on the payer, distribution, pricing and government reporting.

Prior to Covis, Al was with Vivus where he was the Vice President of Market Access focused on the commercial launch of Qsymia. Al spent much of his career with Eli Lilly & Company in a variety of leadership positions with responsibility on the US payer and getting products to market through the US supply chain. Al attended the University of Miami where he received a BA in Marine Affairs.

Theresa Ankamah is the Vice President and head of Medical Affairs for Covis Pharma. Theresa brings over 15 years of experience in Medical Affairs Leadership including Field Medical and Scientific Communications as well as Medical Affairs Strategy through the lifecycle of a product.

Prior to Covis, Theresa held roles of increasing Medical Affairs responsibility in multiple therapeutic areas including hematology/oncology, cardiovascular, neurology, and metabolism to name a few.

Theresa received her Bachelor of Science in Chemistry from the Marymount College of Fordham University, and her Doctorate in Pharmacy from St. John’s University. She went on to complete a post-doctoral fellowship training in Medical Affairs through the Rutgers Institute for Pharmaceutical Industry Fellowships.

Craig Flanagan is the Senior Vice President, US Head of Sales & Marketing for Covis Pharma. He has more than 23 years of commercially focused US and Global industry experience.

Prior to joining Covis, Craig worked for 20 years at Sanofi in several commercial roles of increasing responsibility. During his time at Sanofi he held positions in sales, sales leadership, US/global marketing, training & leadership development, commercial operations, global field excellence and general management. Craig is a graduate of the Pennsylvania State University earning a B.A. in Speech Communications.

Dan Freedman is the Vice President of Clinical Operations and Asset Lead for Ciraparantag. Dan has over 25 years of experience in building and working with cross-functional drug development teams through pre-clinical, clinical, and post-marketing development.

Prior to joining Covis, Dan held roles in Research, Clinical Operations, Regulatory Affairs, and Program Management developing small molecules, biologics and small interfering RNAs across several therapeutic areas at AMAG, Alnylam, Vertex and Biogen.

Dan received his Ph.D. in Molecular and Cellular Biology at the University of Massachusetts and completed his postdoctoral training in the Biological Chemistry and Molecular Pharmacology Department at Harvard Medical School.

John McKenney is the Vice President, US Strategic Accounts and leads the GPO, IDN and DOD contracting business in the US. He brings over 25 years of experience focused on market access, business development and commercial sales. Prior to Covis, John was with AMAG Pharmaceuticals as the Executive Director and Head of Strategic Accounts leading GPO and IDN contracting across both the Oncology and Women’s Health franchises. His expertise in market access spans across several industry leading organizations with increased responsibilities with Guardant Health, R-Pharm US, Dendreon, Sanofi, Johnson & Johnson, Boehringer Ingelheim, Alza, and Vivus. John started his career at TAP Pharmaceuticals.

John received his Bachelor of Applied Science from San Diego State University – California State University.

Brandy Vachtsevanos is the Vice President, US Corporate Accounts for Covis Pharma. She has more than 17 years of experience in the pharmaceutical industry focused on the payer, distribution, and patient programs.

Prior to Covis, Brandy was Director of Trade Accounts and Distribution at Vivus, Inc. In this capacity, she was responsible for leading all trade and distribution activities for Vivus, including the initial limited distribution and subsequent retail launch of Qsymia, as well as, for operationalizing and launching the first hub for reimbursement services at Vivus.

Brandy spent most of her career with Eli Lilly & Company in a variety of roles with increasing responsibility. Prior to joining Lilly, Brandy was a chemical engineer for Honeywell Inc. in the Automation and Control Solutions business working with paper companies, oil refineries, and chemical companies.

Brandy holds a Bachelor of Science in Chemical Engineering from The University of Tennessee and a Master of Business Administration from The Goizueta Business School at Emory University.

Loïc Vandermeeren is the Head of Information Technology of Covis Pharma Group. He has 17 years of experience with more than 14 years in the pharmaceutical industry.

Prior to Covis, Loïc held various roles with increasing responsibility for pharmaceutical companies such as GSK vaccines, Minachem, Ajinomoto and Catalent Pharma Solutions. He also worked as a consultant for pharmaceutical companies of different sizes, leading international project teams for products at different manufacturing stages.

Loïc is also a seasonal lecturer for the industrial engineering program at the Meurice Institute in Brussels.

Loïc received his Masters in Chemistry and holds a Postgraduate degree in Computational Sciences from the UCL university in Belgium. Loïc speaks French and English.

Deborah Zimmermann is the Vice President of Sales for Covis Pharma. She has over 30 years of Healthcare Expertise focused on New Product Launches, Life Cycle Management and Market Access for Pharma and Medical Device.

Prior to Covis, Deborah was Executive Director, Head of Sales for AMAG Pharma. She spent most of her career at Abbott Laboratories/AbbVie in a variety of Divisions and Commercial roles with increasing responsibility. Prior to joining AbbVie, Deborah was a Registered Nurse at Johns Hopkins Medical Center working Critical Care and Bone Marrow Transplant.

Deborah holds a Bachelor of Science in Business Administration from Rowan University and an Executive Development Certificate from the Wharton School of Business.

Mr. Rajiv De Silva is the Managing Partner of Asiri Advisors, a firm focused on advising private equity, and other corporate and financial institutions on the biopharmaceutical sector. He has broad international experience, having managed businesses in the United States, Europe, Canada, Latin America, Asia, South Africa and Australia.

He was President, Chief Executive Officer and Director of Endo International, Plc, a publicly traded multinational pharmaceutical company, from 2013 to 2016. Prior to joining Endo, he served as the President of Valeant Pharmaceuticals International, Inc. from 2010 to 2013 and served as its Chief Operating Officer, Specialty Pharmaceuticals from 2009 to 2013. Prior to joining Valeant, Mr. De Silva held various leadership positions with Novartis AG. He served as President of Novartis Vaccines USA and Head, Vaccines of the Americas at Novartis. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel, Switzerland. Prior to his time at Novartis, Mr. De Silva was a Partner at McKinsey & Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. Mr. De Silva was a Director of AMAG Pharmaceuticals, Inc. from 2012 to 2013. He served on the Board of Rx&D, the Canadian Pharmaceutical Association from 2005 to 2007, was a member of the Board of Trustees of The Kent Place School in Summit, NJ, and is currently a member of the Board of Trustees and Treasurer of The Gill St. Bernard’s School in Gladstone, NJ.

Mr. Rajiv holds a BSE, Honors from Princeton University, an MS from Stanford University and an MBA with Distinction from the Wharton School at the University of Pennsylvania.

Bruno joined AlterDomus in May 2019, and leads global Sales and Relationship Management efforts, as well as the development and implementation of new products and innovation. Previously, Bruno was the Global Head of Private Equity and Real Estate at TMF Group, where he acquired experience in the implementation, management, accounting and administration of private equity and real assets funds and SPVs. Prior to this, Bruno was Head of Corporate Services at AlterDomus for 15 years. Bruno has a degree in Business Studies from IPAG in Paris (as well as in French Accounting).
Gaetan is an Apollo Advisor in Luxembourg who also founded The Square Finance, a privately owned advisory company focused on providing corporate finance, treasure services, compliance, risk management, corporate governance, process and internal organizational services to clients. Gaetan serves as a professional independent director and is certified from various risk management organizations and was the Treasury Manager of the Year in 2016 in the Luxembourg Finance Awards. Gaetan is a member of the board of the ILA (Luxembourg Directors Institute) and ATEL (corporate treasurers). Gaetan has requisite pharma experience as a board member of the Lux board of the UCB group. Gaetan has a degree from HEC Liege University.
Mr. Feinstein is a partner of Apollo, where he has been employed since 2007, and is focused on Apollo’s investments in the chemicals and pharmaceuticals sectors. Previously, he was a member of the Investment Banking Group at Morgan Stanley. Mr. Feinstein currently serves on the board of directors of Covis Pharma and Vacuumshmelze GmbH & Co., and formerly served on the board of directors CEVA Logistics, Hexion Inc., Momentive Performance Materials, Pinnacle Agriculture Holdings, Taminco Global Chemicals and VECTRA Co.
Ibrahim Jabri joined AlterDomus in December 2014 and is a director in the Private Equity and Infrastructure segment based in Luxembourg. He serves as a board member for other multinationals and Private Equity firms. Before AlterDomus, Ibrahim worked for 6 years at PwC Luxembourg in the audit and tax and accounting departments. He also worked at Capital Fiduciary Group. Ibrahim holds a degree in Business Administration from UCL Mons, Belgium and is a member of the Luxembourg Ordre des Experts Compatables (chartered accountants)
Mr. Kiely is a director of two public companies, Zovio Inc., an educational technology company, and Amneal Pharmaceutical, a generic and specialty pharmaceutical company. For both companies, he serves as Audit Committee Chair, and as a member of the Nominating Committee. Mr. Kiely is also a director of the Partnership for A Healthier America, a nonprofit organization.

Mr. Kiely retired from PricewaterhouseCoopers LLP in 2019 where during his 39-year career he had significant leadership roles, including Assurance Chief Quality Officer, Assurance Leader of the Private Equity Sector, and Leader of the U.S Pharmaceutical Industry Sector. During his PwC career, he had extensive experience working with Fortune 500 companies and Private Equity portfolio companies.

Mr. Kiely earned a B.A. from St. Francis University (Pa) and is a certified public accountant.

Mr. Levinson is a Managing Director at Princeton Biopharma Capital Partners, LLC with over 25 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. Prior to joining Princeton Biopharma Capital Partners, LLC, Mr. Levinson was Vice President of Business Development at Valeant Pharma North America LLC, responsible for the business development activities of its specialty pharmaceutical businesses in dermatology, CNS, orphan conditions and ophthalmology. Before Valeant, Mr. Levinson was a founding employee of Aton Pharma, Inc., a specialty pharmaceutical company with products that treated orphan conditions and ophthalmology. As its Vice President of Business Development, Mr. Levinson identified and acquired several key products for Aton and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton’s products to new medical uses, and spearheaded programs to develop these new indications.

Before Aton, Mr. Levinson was Founder and President of Park Life Science Advisory, LLC, where he provided outsourced business development capabilities for life science companies. He was previously a Managing Director at CPP Advisors (now Apeiron Partners), a boutique life sciences strategic advisory group and before that a Director in the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the 10 years prior to KPMG, Mr. Levinson held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (now Bayer Healthcare Pharmaceuticals), most recently as Associate Director of Schering’s Office of Technology. Before Berlex, Mr. Levinson initiated and developed the Protein Biochemistry Group at the biotech startup Ecogen, and served as the company’s Radiation Safety Officer. Mr. Levinson received his PhD and Master’s degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his BA, with highest honors, in Biochemistry from Princeton University.

Clint Lewis has over 30 years of experience in the life sciences, healthcare and pharmaceutical industry having previously held senior executive positions across both human health and animal health at Pfizer and Zoetis. He has worked and resided both in the U.S. and in Europe with extensive international travel.

As Executive Vice President and Group President, International Operations and Commercial Development for Zoetis, Clint served as a corporate officer and member of the Executive Management Team, responsible for setting the over-arching strategy and capital allocation plan for the company. Clint was responsible for all markets outside of the United States with operations in 45 countries and a workforce of over 3,500 people.

Previously, Clint served as the Executive Vice President and President of U.S. Operations at Zoetis. In this role, Clint had responsibility for a $2.5 billion business and a workforce of over 1,200. Clint helped lead the successful �spin-out� and IPO of Zoetis out of Pfizer in 2013. He played a critical role leading the global commercial restructuring, eliminating ~40% of SKUs, exiting 25 markets and reducing SG&A 30% resulting in a cost savings of $180 million.

Prior to the formation of Zoetis, Clint spent 25 years in senior commercial roles of increasing responsibility at Pfizer, Inc. across both human and animal health. Clint currently serves as a member of the Board of Directors for International Paper (NYSE: IP) and serves on the Board�s Governance and Public Policy & Environment sub-committees.

The National Agri-Marketing Association recognized Clint as the Top Agri-Business Leader in the U.S. in 2015. Clint has been profiled in CEO International magazine (Sept. 2016); Black Enterprise Top African Americans in Corporate America (2015) and Savoy Magazine Top 100 Influential African Americans in Corporate America (2014, 2016).

Clint holds a bachelor�s degree in biology from Fairfield University and a Master of Business Administration degree in marketing from Fairleigh Dickinson University.

Ms. Manogue is the former Executive Vice President and Chief Legal Officer of Endo International plc. Ms. Manogue started her career as a deal lawyer at Skadden. Endo was a client when it was still PE owned (by Kelso & Co.). She then moved over to Endo and was General Counsel for 15 years spanning a period that included the company going public through a reverse merger, multiple acquisitions, an inversion transaction, etc. She initially set up the compliance function at the company and was involved in all aspects of legal and regulatory oversight including being the Corporate Secretary. Caroline earned a JD from Fordham University and a BA, cum laude, from Middlebury College.
Michael Porter is the CEO of Covis Pharma. Previously he was COO of Covis Pharma Sarl, where he was responsible for the partial monetization of the business for $1.2 billion. He has over 20 years of private equity experience. Prior to Covis, Michael was with Cerberus Capital Management where he was a Senior Operating Executive.

He was previously with another large distressed private equity fund and began his career at AlixPartners in their Turnaround and Performance Improvement Group.

Michael received his MBA from Columbia Business School with a concentration in Finance via the accelerated program. In addition, he studied International Business at Senshu University in Kawasaki, Japan. Michael speaks English, Spanish, Portuguese, French, Japanese, and Russian.

Xavier joined AlterDomus in October 2016 and is a Team Leader in the Private Equity and Infrastructure segment based in Luxembourg. He serves as a board member for other multinationals and Private Equity firms. Before AlterDomus, Xavier worked JP Morgan Bank Luxembourg as a Company Administration Manager. Xavier has multiple degrees from University of Nancy in France. Xavier is on the Lux boards of Verallia and Watches of Switzerland.
Mr. Saffer is a Principal in the London Private Equity team at Apollo, having joined in 2015. Since he joined Apollo, Mr. Saffer has been involved in various private equity transactions, including OLB, Catalina, Aspen and Gamenet. Mr. Saffer currently serves on the board of directors of Aspen and Gamenet.

Previously, Mr. Saffer was a member of the M&A group at Credit Suisse based in London.

Mr. Saffer graduated from the University of Nottingham with a BSc in Economics.

Mr. Rajiv De Silva is the Managing Partner of Asiri Advisors, a firm focused on advising private equity, and other corporate and financial institutions on the biopharmaceutical sector. He has broad international experience, having managed businesses in the United States, Europe, Canada, Latin America, Asia, South Africa and Australia.

He was President, Chief Executive Officer and Director of Endo International, Plc, a publicly traded multinational pharmaceutical company, from 2013 to 2016. Prior to joining Endo, he served as the President of Valeant Pharmaceuticals International, Inc. from 2010 to 2013 and served as its Chief Operating Officer, Specialty Pharmaceuticals from 2009 to 2013. Prior to joining Valeant, Mr. De Silva held various leadership positions with Novartis AG. He served as President of Novartis Vaccines USA and Head, Vaccines of the Americas at Novartis. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel, Switzerland. Prior to his time at Novartis, Mr. De Silva was a Partner at McKinsey & Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. Mr. De Silva was a Director of AMAG Pharmaceuticals, Inc. from 2012 to 2013. He served on the Board of Rx&D, the Canadian Pharmaceutical Association from 2005 to 2007, was a member of the Board of Trustees of The Kent Place School in Summit, NJ, and is currently a member of the Board of Trustees and Treasurer of The Gill St. Bernard’s School in Gladstone, NJ.

Mr. Rajiv holds a BSE, Honors from Princeton University, an MS from Stanford University and an MBA with Distinction from the Wharton School at the University of Pennsylvania.

Mr. Feinstein is a partner of Apollo, where he has been employed since 2007, and is focused on Apollo’s investments in the chemicals and pharmaceuticals sectors. Previously, he was a member of the Investment Banking Group at Morgan Stanley. Mr. Feinstein currently serves on the board of directors of Covis Pharma and Vacuumshmelze GmbH & Co., and formerly served on the board of directors CEVA Logistics, Hexion Inc., Momentive Performance Materials, Pinnacle Agriculture Holdings, Taminco Global Chemicals and VECTRA Co.
Mr. Kiely is a director of two public companies, Zovio Inc., an educational technology company, and Amneal Pharmaceutical, a generic and specialty pharmaceutical company. For both companies, he serves as Audit Committee Chair, and as a member of the Nominating Committee. Mr. Kiely is also a director of the Partnership for A Healthier America, a nonprofit organization.

Mr. Kiely retired from PricewaterhouseCoopers LLP in 2019 where during his 39-year career he had significant leadership roles, including Assurance Chief Quality Officer, Assurance Leader of the Private Equity Sector, and Leader of the U.S Pharmaceutical Industry Sector. During his PwC career, he had extensive experience working with Fortune 500 companies and Private Equity portfolio companies.

Mr. Kiely earned a B.A. from St. Francis University (Pa) and is a certified public accountant.

Mr. Levinson is a Managing Director at Princeton Biopharma Capital Partners, LLC with over 25 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. Prior to joining Princeton Biopharma Capital Partners, LLC, Mr. Levinson was Vice President of Business Development at Valeant Pharma North America LLC, responsible for the business development activities of its specialty pharmaceutical businesses in dermatology, CNS, orphan conditions and ophthalmology. Before Valeant, Mr. Levinson was a founding employee of Aton Pharma, Inc., a specialty pharmaceutical company with products that treated orphan conditions and ophthalmology. As its Vice President of Business Development, Mr. Levinson identified and acquired several key products for Aton and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton’s products to new medical uses, and spearheaded programs to develop these new indications.

Before Aton, Mr. Levinson was Founder and President of Park Life Science Advisory, LLC, where he provided outsourced business development capabilities for life science companies. He was previously a Managing Director at CPP Advisors (now Apeiron Partners), a boutique life sciences strategic advisory group and before that a Director in the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the 10 years prior to KPMG, Mr. Levinson held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (now Bayer Healthcare Pharmaceuticals), most recently as Associate Director of Schering’s Office of Technology. Before Berlex, Mr. Levinson initiated and developed the Protein Biochemistry Group at the biotech startup Ecogen, and served as the company’s Radiation Safety Officer. Mr. Levinson received his PhD and Master’s degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his BA, with highest honors, in Biochemistry from Princeton University.

Clint Lewis has over 30 years of experience in the life sciences, healthcare and pharmaceutical industry having previously held senior executive positions across both human health and animal health at Pfizer and Zoetis. He has worked and resided both in the U.S. and in Europe with extensive international travel.

As Executive Vice President and Group President, International Operations and Commercial Development for Zoetis, Clint served as a corporate officer and member of the Executive Management Team, responsible for setting the over-arching strategy and capital allocation plan for the company. Clint was responsible for all markets outside of the United States with operations in 45 countries and a workforce of over 3,500 people.

Previously, Clint served as the Executive Vice President and President of U.S. Operations at Zoetis. In this role, Clint had responsibility for a $2.5 billion business and a workforce of over 1,200. Clint helped lead the successful �spin-out� and IPO of Zoetis out of Pfizer in 2013. He played a critical role leading the global commercial restructuring, eliminating ~40% of SKUs, exiting 25 markets and reducing SG&A 30% resulting in a cost savings of $180 million.

Prior to the formation of Zoetis, Clint spent 25 years in senior commercial roles of increasing responsibility at Pfizer, Inc. across both human and animal health. Clint currently serves as a member of the Board of Directors for International Paper (NYSE: IP) and serves on the Board�s Governance and Public Policy & Environment sub-committees.

The National Agri-Marketing Association recognized Clint as the Top Agri-Business Leader in the U.S. in 2015. Clint has been profiled in CEO International magazine (Sept. 2016); Black Enterprise Top African Americans in Corporate America (2015) and Savoy Magazine Top 100 Influential African Americans in Corporate America (2014, 2016).

Clint holds a bachelor�s degree in biology from Fairfield University and a Master of Business Administration degree in marketing from Fairleigh Dickinson University.

Ms. Manogue is the former Executive Vice President and Chief Legal Officer of Endo International plc. Ms. Manogue started her career as a deal lawyer at Skadden. Endo was a client when it was still PE owned (by Kelso & Co.). She then moved over to Endo and was General Counsel for 15 years spanning a period that included the company going public through a reverse merger, multiple acquisitions, an inversion transaction, etc. She initially set up the compliance function at the company and was involved in all aspects of legal and regulatory oversight including being the Corporate Secretary. Caroline earned a JD from Fordham University and a BA, cum laude, from Middlebury College.
Michael Porter is the CEO of Covis Pharma. Previously he was COO of Covis Pharma Sarl, where he was responsible for the partial monetization of the business for $1.2 billion. He has over 20 years of private equity experience. Prior to Covis, Michael was with Cerberus Capital Management where he was a Senior Operating Executive.

He was previously with another large distressed private equity fund and began his career at AlixPartners in their Turnaround and Performance Improvement Group.

Michael received his MBA from Columbia Business School with a concentration in Finance via the accelerated program. In addition, he studied International Business at Senshu University in Kawasaki, Japan. Michael speaks English, Spanish, Portuguese, French, Japanese, and Russian.

Mr. Saffer is a Principal in the London Private Equity team at Apollo, having joined in 2015. Since he joined Apollo, Mr. Saffer has been involved in various private equity transactions, including OLB, Catalina, Aspen and Gamenet. Mr. Saffer currently serves on the board of directors of Aspen and Gamenet.

Previously, Mr. Saffer was a member of the M&A group at Credit Suisse based in London.

Mr. Saffer graduated from the University of Nottingham with a BSc in Economics.

Executive Team

Hidden
Chief Executive Officer

Michael Porter is the CEO of Covis Pharma. Previously he was COO of Covis Pharma Sarl, where he was responsible for the partial monetization of the business for $1.2 billion. He has over 20 years of private equity experience. Prior to Covis, Michael was with Cerberus Capital Management where he was a Senior Operating Executive.

He was previously with another large distressed private equity fund and began his career at AlixPartners in their Turnaround and Performance Improvement Group.

Michael received his MBA from Columbia Business School with a concentration in Finance via the accelerated program. In addition, he studied International Business at Senshu University in Kawasaki, Japan. Michael speaks English, Spanish, Portuguese, French, Japanese, and Russian.

Chief Human Resources Officer

Martin Cepeda is the Chief Human Resources Officer of Covis Pharma. Prior to joining Covis, Martin worked at AstraZeneca as Head of Human Resources for the Europe Oncology Business, based in Zug, Switzerland, >$2 billion in annual revenue and ~1,750 employees. He was also a member of AstraZeneca’s Inclusion and Diversity (I&D) Council chaired by the CEO, driving the company’s global I&D strategy. Martin brings over 16 years of Global HR experience across multinational pharmaceutical and life science companies.

Prior to AstraZeneca, Martin worked in HR roles of increasing responsibility at Johnson & Johnson and Wyeth (acquired by Pfizer in 2009). In those companies, he held roles in HR Data, Insights and Analytics, Talent Acquisition, and various HR Business Partner roles based in the U.S. and Europe.

Martin received his B.S. in Business Management from Penn State University and his MBA in International Business from Villanova University, both located in the U.S.

Chief Innovation Officer

Raghav Chari has 25 years’ experience in the biopharmaceutical arena. Over this period, he has successfully built and led small and large organizations across the R&D and commercialization continuum.

Over the last 5 years, he has founded and continues to be involved in several startups that work at the interface between drug discovery and technology. All these startups seek to improve how novel products are discovered and developed by utilizing approaches involving machine learning, quantum mechanics and various technologies for personalized medicine.

From 2009 through 2016, he was President of Promius Pharma, a dermatology and neurology company, and Executive Vice President of Proprietary Products at Dr. Reddy’s Laboratories. In this role he built an integrated R&D and Commercial business which led to several first cycle NDA approvals for products that were developed organically from inception through commercial launch.

He has also been responsible for over 50 licensing and product development deals in the biopharmaceutical space. Early in his career, Raghav worked at McKinsey and Company, followed by stints at two small drug discovery/early development-stage biotech companies where he played hybrid R&D and commercial roles.

Raghav has a PhD in Physics from Princeton University, and a BS in Mathematics from the California Institute of Technology.

Executive Vice President, Quality Assurance and Technology Transfers

Fabio Fazio is Executive Vice President, Quality Assurance and Technology Transfers. He ensures compliance of pharmaceutical production to good manufacturing practice and to Marketing Authorizations. Fabio is responsible for the implementation of the quality systems which include the management of regulatory inspections, supplier oversight and audits, technology transfers, and adherence to good distribution practice.

Prior to Covis, Fabio worked at Biogen Idec as Qualified Person and in other technical CMC roles. Previous experiences encompass Process Development at GlaxoSmithKline in support of early stage clinical trials and basic research of novel therapeutic agents at the Scripps Research Institute in La Jolla, CA.

Fabio graduated from the Faculty of Pharmacy at the University of Siena, Italy, and received his Ph.D. in Chemistry from the University of Wuppertal, Germany.

Senior Vice President and General Manager Canada, EU and ROW

Jim is currently the Senior Vice President and General Manager at Covis Pharma Canada, EU and ROW. Prior to joining Covis, Jim held senior level commercial roles at several multinational pharmaceutical companies, and has more than 30 years of pharmaceutical industry experience in general management, sales, marketing, market access, operations and business development.

In 2017, Jim was inducted into the Canadian Pharmaceutical Marketers Hall of Fame for his contributions to the industry and his support in the development of others.

For the past 8 years, Jim has been a seasonal lecturer in the MBA program at the DeGroote School of Business in Hamilton, Ontario.

Jim received his Bachelor of Engineering Science degree from the University of Western Ontario and Master of Business Administration from McMaster University.

Executive Vice President, Regulatory and Scientific Affairs

Aziza Johnson is the Executive Vice President of Regulatory and Scientific Affairs. She has over 18 years of progressive global regulatory experience in the pharmaceutical industry leading project teams from early development through to commercial launch. Aziza has been active in all her roles and has led projects through start up, launch, survival, and growth.

Prior to Covis, Aziza worked in a variety of environments (small, medium, and large pharmaceutical organizations) with increasing roles and responsibility and in more recent years, including management roles. In addition, Aziza worked at the Medicines and Healthcare Regulatory Agency as a pharmaceutical assessor, where she gained useful insight into the operations of the UK Regulatory agency. Aziza attended the University of London School of Pharmacy and the University of Leicester where she received her B.Pharm. (Hons.) and Masters in Law respectively.

Senior Vice President, Supply Chain

Nick Kelly is the Senior Vice President of Supply Chain. He has over 20 years of supply chain experience as a management consultant across multiple industries as well as within the pharmaceutical industry across branded, generics and medical device organizations.

Prior to Covis, Nick held several senior management roles at the regional & global level within the pharmaceutical industry, including Cardinal Health, Teva and Johnson & Johnson.

He has solid strategic, tactical and operational management experience, developing and maintaining relationships across the E2E supply chain to ensure an efficient operation.

Nick attended the University of Westminster where he received his BSc (Hons) in Business Information Technology.

Chief Financial Officer

Ozgur Kilic is the Global CFO of Covis Pharma. Previously Ozgur was the CFO of Vertice Pharma, a specialty generic pharma company in the U.S., backed by Warburg Pincus. Ozgur brings over 17 years of healthcare finance experience ranging from branded and generic pharmaceuticals to vaccines and medical devices both in the U.S. and Europe.

Prior to Vertice, Ozgur spent 14 years at Novartis in progressive Finance roles including Country and Region CFO roles in Switzerland, U.K., Italy and the U.S. He has significant experience in partnering with commercial, manufacturing, R&D and BD&L / M&A teams at operational and strategical level to drive business results.

Ozgur received his B.A. in Business Administration from Koc University in Turkey, MBA in Finance and Investment with distinction from Stuttgart Institute of Management Technology (SIMT), Germany and Executive Education in Finance from Harvard Business School. Ozgur is a Chartered Management Accountant (CIMA UK) and speaks English, Turkish, Italian and German.

General Counsel and Group Corporate Secretary

Francesco Tallarico is the General Counsel and Group Corporate Secretary of Covis Pharma Group.

Prior to joining Covis, Mr. Tallarico served as the Chief Legal Officer and Corporate Secretary at The Flowr Corporation, a federally licensed global cannabis producer listed on the TSX-V. At Flowr, Mr. Tallarico managed all aspects of the legal and regulatory function of the company, including having led the company’s M&A and corporate finance transactions valued at over CAD$340 million.

Prior to Flowr, Mr. Tallarico served as the Chief Legal Officer and Corporate Secretary at Concordia International Corp. (now Advanz Pharma), a global specialty pharmaceutical company previously listed on the TSX and NASDAQ. At Concordia, Mr. Tallarico led the global legal and compliance functions, including having led Concordia’s M&A transactions valued at over USD$4.5 billion and corporate restructuring that resulted in Concordia reducing its debt by approximately USD$2.4 billion. Before joining Concordia, Mr. Tallarico practiced law in Toronto at Fasken Martineau DuMoulin LLP, specializing in corporate finance, M&A and securities matters.

Mr. Tallarico received his Bachelor of Arts from the University of Toronto and his Juris Doctor from the University of Windsor.

US President

Al Tenuto is the US President for Covis Pharma. He has more than 20 years of experience in the pharmaceutical industry and more than 15 years focused on the payer, distribution, pricing and government reporting.

Prior to Covis, Al was with Vivus where he was the Vice President of Market Access focused on the commercial launch of Qsymia. Al spent much of his career with Eli Lilly & Company in a variety of leadership positions with responsibility on the US payer and getting products to market through the US supply chain. Al attended the University of Miami where he received a BA in Marine Affairs.

Vice Presidents

Hidden
Vice President, Medical Affairs

Theresa Ankamah is the Vice President and head of Medical Affairs for Covis Pharma. Theresa brings over 15 years of experience in Medical Affairs Leadership including Field Medical and Scientific Communications as well as Medical Affairs Strategy through the lifecycle of a product.

Prior to Covis, Theresa held roles of increasing Medical Affairs responsibility in multiple therapeutic areas including hematology/oncology, cardiovascular, neurology, and metabolism to name a few.

Theresa received her Bachelor of Science in Chemistry from the Marymount College of Fordham University, and her Doctorate in Pharmacy from St. John’s University. She went on to complete a post-doctoral fellowship training in Medical Affairs through the Rutgers Institute for Pharmaceutical Industry Fellowships.

Senior Vice President, US Head of Sales & Marketing

Craig Flanagan is the Senior Vice President, US Head of Sales & Marketing for Covis Pharma. He has more than 23 years of commercially focused US and Global industry experience.

Prior to joining Covis, Craig worked for 20 years at Sanofi in several commercial roles of increasing responsibility. During his time at Sanofi he held positions in sales, sales leadership, US/global marketing, training & leadership development, commercial operations, global field excellence and general management. Craig is a graduate of the Pennsylvania State University earning a B.A. in Speech Communications.

Vice President of Clinical Operations

Dan Freedman is the Vice President of Clinical Operations and Asset Lead for Ciraparantag. Dan has over 25 years of experience in building and working with cross-functional drug development teams through pre-clinical, clinical, and post-marketing development.

Prior to joining Covis, Dan held roles in Research, Clinical Operations, Regulatory Affairs, and Program Management developing small molecules, biologics and small interfering RNAs across several therapeutic areas at AMAG, Alnylam, Vertex and Biogen.

Dan received his Ph.D. in Molecular and Cellular Biology at the University of Massachusetts and completed his postdoctoral training in the Biological Chemistry and Molecular Pharmacology Department at Harvard Medical School.

Vice President, US Strategic Accounts

John McKenney is the Vice President, US Strategic Accounts and leads the GPO, IDN and DOD contracting business in the US. He brings over 25 years of experience focused on market access, business development and commercial sales. Prior to Covis, John was with AMAG Pharmaceuticals as the Executive Director and Head of Strategic Accounts leading GPO and IDN contracting across both the Oncology and Women’s Health franchises. His expertise in market access spans across several industry leading organizations with increased responsibilities with Guardant Health, R-Pharm US, Dendreon, Sanofi, Johnson & Johnson, Boehringer Ingelheim, Alza, and Vivus. John started his career at TAP Pharmaceuticals.

John received his Bachelor of Applied Science from San Diego State University – California State University.

Vice President, US Corporate Accounts

Brandy Vachtsevanos is the Vice President, US Corporate Accounts for Covis Pharma. She has more than 17 years of experience in the pharmaceutical industry focused on the payer, distribution, and patient programs.

Prior to Covis, Brandy was Director of Trade Accounts and Distribution at Vivus, Inc. In this capacity, she was responsible for leading all trade and distribution activities for Vivus, including the initial limited distribution and subsequent retail launch of Qsymia, as well as, for operationalizing and launching the first hub for reimbursement services at Vivus.

Brandy spent most of her career with Eli Lilly & Company in a variety of roles with increasing responsibility. Prior to joining Lilly, Brandy was a chemical engineer for Honeywell Inc. in the Automation and Control Solutions business working with paper companies, oil refineries, and chemical companies.

Brandy holds a Bachelor of Science in Chemical Engineering from The University of Tennessee and a Master of Business Administration from The Goizueta Business School at Emory University.

Head of Information Technology

Loïc Vandermeeren is the Head of Information Technology of Covis Pharma Group. He has 17 years of experience with more than 14 years in the pharmaceutical industry.

Prior to Covis, Loïc held various roles with increasing responsibility for pharmaceutical companies such as GSK vaccines, Minachem, Ajinomoto and Catalent Pharma Solutions. He also worked as a consultant for pharmaceutical companies of different sizes, leading international project teams for products at different manufacturing stages.

Loïc is also a seasonal lecturer for the industrial engineering program at the Meurice Institute in Brussels.

Loïc received his Masters in Chemistry and holds a Postgraduate degree in Computational Sciences from the UCL university in Belgium. Loïc speaks French and English.

Vice President, Head of Sales, Hem/Onc

Deborah Zimmermann is the Vice President of Sales for Covis Pharma. She has over 30 years of Healthcare Expertise focused on New Product Launches, Life Cycle Management and Market Access for Pharma and Medical Device.

Prior to Covis, Deborah was Executive Director, Head of Sales for AMAG Pharma. She spent most of her career at Abbott Laboratories/AbbVie in a variety of Divisions and Commercial roles with increasing responsibility. Prior to joining AbbVie, Deborah was a Registered Nurse at Johns Hopkins Medical Center working Critical Care and Bone Marrow Transplant.

Deborah holds a Bachelor of Science in Business Administration from Rowan University and an Executive Development Certificate from the Wharton School of Business.

Board of Directors

* An asterisk denotes Board members who are also on the Advisory Board

Hidden
Chairman

Mr. Rajiv De Silva is the Managing Partner of Asiri Advisors, a firm focused on advising private equity, and other corporate and financial institutions on the biopharmaceutical sector. He has broad international experience, having managed businesses in the United States, Europe, Canada, Latin America, Asia, South Africa and Australia.

He was President, Chief Executive Officer and Director of Endo International, Plc, a publicly traded multinational pharmaceutical company, from 2013 to 2016. Prior to joining Endo, he served as the President of Valeant Pharmaceuticals International, Inc. from 2010 to 2013 and served as its Chief Operating Officer, Specialty Pharmaceuticals from 2009 to 2013. Prior to joining Valeant, Mr. De Silva held various leadership positions with Novartis AG. He served as President of Novartis Vaccines USA and Head, Vaccines of the Americas at Novartis. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel, Switzerland. Prior to his time at Novartis, Mr. De Silva was a Partner at McKinsey & Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. Mr. De Silva was a Director of AMAG Pharmaceuticals, Inc. from 2012 to 2013. He served on the Board of Rx&D, the Canadian Pharmaceutical Association from 2005 to 2007, was a member of the Board of Trustees of The Kent Place School in Summit, NJ, and is currently a member of the Board of Trustees and Treasurer of The Gill St. Bernard’s School in Gladstone, NJ.

Mr. Rajiv holds a BSE, Honors from Princeton University, an MS from Stanford University and an MBA with Distinction from the Wharton School at the University of Pennsylvania.

Products and Innovation Group Head, Alter Domus

Bruno joined AlterDomus in May 2019, and leads global Sales and Relationship Management efforts, as well as the development and implementation of new products and innovation. Previously, Bruno was the Global Head of Private Equity and Real Estate at TMF Group, where he acquired experience in the implementation, management, accounting and administration of private equity and real assets funds and SPVs. Prior to this, Bruno was Head of Corporate Services at AlterDomus for 15 years. Bruno has a degree in Business Studies from IPAG in Paris (as well as in French Accounting).

Apollo Advisor and Founder of The Square Finance

Gaetan is an Apollo Advisor in Luxembourg who also founded The Square Finance, a privately owned advisory company focused on providing corporate finance, treasure services, compliance, risk management, corporate governance, process and internal organizational services to clients. Gaetan serves as a professional independent director and is certified from various risk management organizations and was the Treasury Manager of the Year in 2016 in the Luxembourg Finance Awards. Gaetan is a member of the board of the ILA (Luxembourg Directors Institute) and ATEL (corporate treasurers). Gaetan has requisite pharma experience as a board member of the Lux board of the UCB group. Gaetan has a degree from HEC Liege University.

Partner, Apollo Global Management

Mr. Feinstein is a partner of Apollo, where he has been employed since 2007, and is focused on Apollo’s investments in the chemicals and pharmaceuticals sectors. Previously, he was a member of the Investment Banking Group at Morgan Stanley. Mr. Feinstein currently serves on the board of directors of Covis Pharma and Vacuumshmelze GmbH & Co., and formerly served on the board of directors CEVA Logistics, Hexion Inc., Momentive Performance Materials, Pinnacle Agriculture Holdings, Taminco Global Chemicals and VECTRA Co.

Director, Alter Domus

Ibrahim Jabri joined AlterDomus in December 2014 and is a director in the Private Equity and Infrastructure segment based in Luxembourg. He serves as a board member for other multinationals and Private Equity firms. Before AlterDomus, Ibrahim worked for 6 years at PwC Luxembourg in the audit and tax and accounting departments. He also worked at Capital Fiduciary Group. Ibrahim holds a degree in Business Administration from UCL Mons, Belgium and is a member of the Luxembourg Ordre des Experts Compatables (chartered accountants)

Director, Zovio Inc. & Amneal Pharmaceutical

Mr. Kiely is a director of two public companies, Zovio Inc., an educational technology company, and Amneal Pharmaceutical, a generic and specialty pharmaceutical company. For both companies, he serves as Audit Committee Chair, and as a member of the Nominating Committee. Mr. Kiely is also a director of the Partnership for A Healthier America, a nonprofit organization.

Mr. Kiely retired from PricewaterhouseCoopers LLP in 2019 where during his 39-year career he had significant leadership roles, including Assurance Chief Quality Officer, Assurance Leader of the Private Equity Sector, and Leader of the U.S Pharmaceutical Industry Sector. During his PwC career, he had extensive experience working with Fortune 500 companies and Private Equity portfolio companies.

Mr. Kiely earned a B.A. from St. Francis University (Pa) and is a certified public accountant.

Managing Director, Princeton Biopharma

Mr. Levinson is a Managing Director at Princeton Biopharma Capital Partners, LLC with over 25 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. Prior to joining Princeton Biopharma Capital Partners, LLC, Mr. Levinson was Vice President of Business Development at Valeant Pharma North America LLC, responsible for the business development activities of its specialty pharmaceutical businesses in dermatology, CNS, orphan conditions and ophthalmology. Before Valeant, Mr. Levinson was a founding employee of Aton Pharma, Inc., a specialty pharmaceutical company with products that treated orphan conditions and ophthalmology. As its Vice President of Business Development, Mr. Levinson identified and acquired several key products for Aton and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton’s products to new medical uses, and spearheaded programs to develop these new indications.

Before Aton, Mr. Levinson was Founder and President of Park Life Science Advisory, LLC, where he provided outsourced business development capabilities for life science companies. He was previously a Managing Director at CPP Advisors (now Apeiron Partners), a boutique life sciences strategic advisory group and before that a Director in the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the 10 years prior to KPMG, Mr. Levinson held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (now Bayer Healthcare Pharmaceuticals), most recently as Associate Director of Schering’s Office of Technology. Before Berlex, Mr. Levinson initiated and developed the Protein Biochemistry Group at the biotech startup Ecogen, and served as the company’s Radiation Safety Officer. Mr. Levinson received his PhD and Master’s degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his BA, with highest honors, in Biochemistry from Princeton University.

Former EVP and Group President, Zoetis

Clint Lewis has over 30 years of experience in the life sciences, healthcare and pharmaceutical industry having previously held senior executive positions across both human health and animal health at Pfizer and Zoetis. He has worked and resided both in the U.S. and in Europe with extensive international travel.

As Executive Vice President and Group President, International Operations and Commercial Development for Zoetis, Clint served as a corporate officer and member of the Executive Management Team, responsible for setting the over-arching strategy and capital allocation plan for the company. Clint was responsible for all markets outside of the United States with operations in 45 countries and a workforce of over 3,500 people.

Previously, Clint served as the Executive Vice President and President of U.S. Operations at Zoetis. In this role, Clint had responsibility for a $2.5 billion business and a workforce of over 1,200. Clint helped lead the successful �spin-out� and IPO of Zoetis out of Pfizer in 2013. He played a critical role leading the global commercial restructuring, eliminating ~40% of SKUs, exiting 25 markets and reducing SG&A 30% resulting in a cost savings of $180 million.

Prior to the formation of Zoetis, Clint spent 25 years in senior commercial roles of increasing responsibility at Pfizer, Inc. across both human and animal health. Clint currently serves as a member of the Board of Directors for International Paper (NYSE: IP) and serves on the Board�s Governance and Public Policy & Environment sub-committees.

The National Agri-Marketing Association recognized Clint as the Top Agri-Business Leader in the U.S. in 2015. Clint has been profiled in CEO International magazine (Sept. 2016); Black Enterprise Top African Americans in Corporate America (2015) and Savoy Magazine Top 100 Influential African Americans in Corporate America (2014, 2016).

Clint holds a bachelor�s degree in biology from Fairfield University and a Master of Business Administration degree in marketing from Fairleigh Dickinson University.

Former EVP and Chief Legal Office, Endo Pharmaceuticals

Ms. Manogue is the former Executive Vice President and Chief Legal Officer of Endo International plc. Ms. Manogue started her career as a deal lawyer at Skadden. Endo was a client when it was still PE owned (by Kelso & Co.). She then moved over to Endo and was General Counsel for 15 years spanning a period that included the company going public through a reverse merger, multiple acquisitions, an inversion transaction, etc. She initially set up the compliance function at the company and was involved in all aspects of legal and regulatory oversight including being the Corporate Secretary. Caroline earned a JD from Fordham University and a BA, cum laude, from Middlebury College.

Chief Executive Officer

Michael Porter is the CEO of Covis Pharma. Previously he was COO of Covis Pharma Sarl, where he was responsible for the partial monetization of the business for $1.2 billion. He has over 20 years of private equity experience. Prior to Covis, Michael was with Cerberus Capital Management where he was a Senior Operating Executive.

He was previously with another large distressed private equity fund and began his career at AlixPartners in their Turnaround and Performance Improvement Group.

Michael received his MBA from Columbia Business School with a concentration in Finance via the accelerated program. In addition, he studied International Business at Senshu University in Kawasaki, Japan. Michael speaks English, Spanish, Portuguese, French, Japanese, and Russian.

Senior Legal Manager and Team Leader, Alter Domus

Xavier joined AlterDomus in October 2016 and is a Team Leader in the Private Equity and Infrastructure segment based in Luxembourg. He serves as a board member for other multinationals and Private Equity firms. Before AlterDomus, Xavier worked JP Morgan Bank Luxembourg as a Company Administration Manager. Xavier has multiple degrees from University of Nancy in France. Xavier is on the Lux boards of Verallia and Watches of Switzerland.

Principal, Apollo Global Management

Mr. Saffer is a Principal in the London Private Equity team at Apollo, having joined in 2015. Since he joined Apollo, Mr. Saffer has been involved in various private equity transactions, including OLB, Catalina, Aspen and Gamenet. Mr. Saffer currently serves on the board of directors of Aspen and Gamenet.

Previously, Mr. Saffer was a member of the M&A group at Credit Suisse based in London.

Mr. Saffer graduated from the University of Nottingham with a BSc in Economics.

Partnerships

We partner with the world’s leading pharmaceutical companies and contract manufacturing organizations to deliver an uninterrupted supply of high-quality pharmaceuticals.

Operational Capabilities

Covis has unparalleled expertise across all functional areas with a flawless history of executing commercial onboarding, tech transferring, and launching authorized generic and line extension products.

Business Development

Covis is always evaluating products and corporate acquisition opportunities with significant resources committed from its equity sponsors for tack-on deals and larger transaction opportunities. For all partnering inquiries, please contact us.

Product Development

Covis is devoted to developing new therapeutic solutions to improve patients’ quality of life through line extensions of its existing portfolio as well as selected novel late-stage clinical programs.

Our Operating Partners

Our Business Development Partners

Our Authorized Distributors of Record

Asia-Pacific

Europe

United States

Brazil and Mexico

South Africa

Products

Respiratory and Allergy

Oncology

Speciality

Cardiovascular

Gastroenterology and CNS

Authorized Generics

Distributor of Record:
Actavis Pharma, Inc.

Prescribing information

Distributor of Record:
Prasco Laboratories

Prescribing information

Distributor of Record:
Rising Pharmaceuticals, Inc.

Prescribing information

State Disclosure

Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131.

State Disclosures last updated May 2021.

Product information is intended for residents of the United States only. Lanoxin® is a registered trademark of the GlaxoSmithKline group of companies. Rilutek®, Betapace®, BetapaceAF®, Altoprev®, Sular®, Alvesco®, Omnaris®, and Zetonna® are registered trademarks of Covis Pharma GmbH.

Co-Pay

Covis’ co-pay program ensures patients always have access to their therapy of choice.

News

Careers

Covis Pharma is a leading, global specialty pharmaceutical company that is focused on providing therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Our paramount concern is patient outcomes and focus on improving the lives of people with serious medical conditions. Headquartered in Luxembourg with operations in Switzerland, the United States, Canada and the Netherlands, Covis Pharma’s success is driven by a team of over 275 employees worldwide.

Covis Pharma was founded in 2011 and is supported by Apollo Capital Management, a global investment manager firm with over $440 billion AUM. We are well-capitalized and continuously evaluate product and corporate acquisition opportunities, ranging from add-ons to transformative M&A, as well as internal product development. Covis Pharma has expanded its geographic reach from the US to over 50 countries around the world and established therapeutic franchises in respiratory, hospital, and specialty through novel commercialization and development strategies. We continue to evolve as a leader in the global healthcare landscape and remain steadfast in our commitment to providing highly efficacious therapeutic solutions to patients at affordable prices.

The ethos at Covis Pharma is focused on five key pillars:

  1. Collaboration – with all stakeholders ensuring access to their ‘best in class’ products for all patients, including those in most need;
  2. Diversification – firm believers in corporate diversity;
  3. Development – focusing on developing and extending therapeutic solutions for patients and physicians globally, and professional growth for employees and partners;
  4. Entrepreneurial – striving to create new opportunities that deliver results for all stakeholders; and
  5. Integrity – strong governance and compliance, to ensure ethical behaviour in all interactions and work they do.

If you are looking to be part of a dynamic, fast-growing organization, have a positive disposition, are willing to develop yourself, and feel passionate about being part of improving the health of others, Covis Pharma would be an ideal fit.

The product information on this website is intended only for residents of the United States.
The products discussed herein may have different labeling in different countries.
© Copyright 2017-2021 Covis Pharma. All rights reserved.

Skip to content